We have compiled a list of manufacturers, distributors, product information, reference prices, and rankings for Drugs for treating diseases.
ipros is IPROS GMS ・ IPROS One of the largest technical database sites in Japan that collects information on.

Drugs for treating diseases - List of Manufacturers, Suppliers, Companies and Products | IPROS GMS

Drugs for treating diseases Product List

1～5 item / All 5 items

Displayed results
Tohoku Univ. Technology :PPARα agonists that improve cognitive function: T22-091

Tohoku Univ. Technology :PPARα agonists that improve cognitive function: T22-091

New drug discovery seeds for psychiatric disorders such as schizophrenia

Recent large-scale genomic and postmortem brain analyses have indicated that synaptic dysgenesis may be involved in the pathogenesis of schizophrenia, but the detailed mechanisms remain unclear. Drugs mainly blocking dopamine D2 receptors have been used for the treatment of schizophrenia, but they are mainly used for symptomatic treatment and have insufficient effects on negative symptoms and cognitive dysfunction. Therefore, it is desirable to develop new drugs based on new molecular mechanisms.　 　The inventors have discovered that the decreased function of the PPARA gene, which encodes the nuclear receptor PPARα, is involved in the pathogenesis of schizophrenia [1]. Since PPARα is a transcription factor that can be activated by its ligand, they considered the possibility that activation of PPARA might lead to the improvement of schizophrenia, and found that fenofibrate, a PPARa agonist, is actually effective in improving synaptic function [2]. In this study, they found that pemafibrate, a PPARa agonist, helps to improve cognitive function at the same time as restoring spine density in mice. The invention could lead to the discovery of novel mechanisms for schizophrenia. Furthermore, since decreased spine density and cognitive decline are similar symptoms in other psychiatric disorders such as Alzheimer's, it could also be a therapeutic agent for these disorders.

  • others
  • Drugs for treating diseases

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Tohoku University Technology: Candidate of therapeutic drug for muscular dystrophy: T16-108

Tohoku University Technology: Candidate of therapeutic drug for muscular dystrophy: T16-108

Metformin helps to repair skeletal muscle!

During sarcolemma repair process, dysferlin protein accumulates at injury part. Dysferlin gene mutation is found in dysferlinopathy, which is a type of muscular dystrophy. Inventors have shown that AMPK, which regulates energy metabolism, binds membrane repair protein dysferlin. Administration of metformin, one of the AMPK activator, improves cell membrane repair in dysferlinopathy.　 　This invention proposes to use metformin, well known therapeutic drug for diabete, as an activator of sarcolemma repair, and to use it as a therapeutic drug for muscular disease such as muscular dystrophy and various diseases that present cell membrane fragility. Features・Outstandings

  • others
  • Drugs for treating diseases

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
[Research Material] Global Market for Non-Alcoholic Fatty Liver Disease Treatment

[Research Material] Global Market for Non-Alcoholic Fatty Liver Disease Treatment

Global Market for Non-Alcoholic Fatty Liver Disease Treatment: Antioxidants, Thiazolidinediones, Biguanides, Lipid-Lowering Agents, FXR Receptor Agonists, etc.

This research report (Global Non-Alcoholic Fatty Liver Disease Treatment Market) investigates and analyzes the current status and outlook for the global market for non-alcoholic fatty liver disease treatment over the next five years. It includes information on the overview of the global non-alcoholic fatty liver disease treatment market, trends of major companies (sales, selling prices, market share), market size by segment, market size by major regions, and distribution channel analysis. The segments by type in the non-alcoholic fatty liver disease treatment market include antioxidants, thiazolidinediones, biguanides, lipid-lowering agents, FXR receptor agonists, and others. The segments by application include hospital pharmacies, retail pharmacies, drugstores, online pharmacies, and others. The regional segments are divided into North America, the United States, Europe, Asia-Pacific, Japan, China, India, South Korea, Southeast Asia, South America, the Middle East, and Africa, calculating the market size for non-alcoholic fatty liver disease treatment. It also includes the market share of major companies in the non-alcoholic fatty liver disease treatment sector, product and business overviews, and sales performance.

  • Other services
  • Drugs for treating diseases

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
[Research Material] Global Market for Lipid Metabolism Disease Treatment

[Research Material] Global Market for Lipid Metabolism Disease Treatment

Global Market for Lipid Metabolism Disorder Treatments: OTC, Prescription Drugs, Hospitals, Retail Pharmacies

This research report (Global Lipid Metabolism Disease Treatment Market) investigates and analyzes the current state and outlook for the global lipid metabolism disease treatment market over the next five years. It includes information on the overview of the global lipid metabolism disease treatment market, trends of major companies (sales, selling prices, market share), market size by segment, market size by major regions, and distribution channel analysis. The segments by type in the lipid metabolism disease treatment market focus on OTC and prescription drugs, while the segments by application target hospitals and retail pharmacies. The regional segments calculate the market size for lipid metabolism disease treatment by dividing it into North America, the United States, Europe, Asia-Pacific, Japan, China, India, South Korea, Southeast Asia, South America, the Middle East, and Africa. It also includes the market share of major companies in lipid metabolism disease treatment, product and business overviews, and sales performance.

  • Other services
  • Drugs for treating diseases

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
[Market Report] Global Inflammatory Bowel Disease Treatment Market

[Market Report] Global Inflammatory Bowel Disease Treatment Market

The global inflammatory bowel disease treatment market is expected to achieve steady growth, reaching 34 billion USD by 2031.

The global inflammatory bowel disease (IBD) treatment market is on an upward trajectory, with revenues reaching approximately $22 billion in 2022, and an estimated value of $34 billion by 2031. This significant growth is projected to occur at a compound annual growth rate (CAGR) of 5.1% during the forecast period from 2023 to 2031. Inflammatory bowel disease (IBD) is a chronic condition characterized by inflammation of the gastrointestinal tract. It primarily consists of two distinct conditions: Crohn's disease and ulcerative colitis. Crohn's disease is known for causing inflammation and discomfort in various parts of the gastrointestinal tract, often affecting the small intestine and the upper part of the large intestine. On the other hand, ulcerative colitis primarily causes pain and inflammation in the colon. You can check the application method by clicking the [PDF Download] button or apply directly through the related links.

  • others
  • Drugs for treating diseases

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Related Categories of Drugs for treating diseases

COPYRIGHT © 2001-2026 IPROS CORPORATION ALL RIGHTS RESERVED.